

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6826)

PROFIT WARNING

This announcement is made by Shanghai Haohai Biological Technology Co., Ltd.* (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Law of Hong Kong).

The board of directors of the Company (the “**Board**”) hereby informs the shareholders of the Company (“**Shareholders**”) and potential investors that, based on the information currently available to the Board and its preliminary review of the unaudited consolidated management accounts of the Group for the six-months ended 30 June 2020 (the “**Reporting Period**”), it is expected that the Group would record an unaudited net profit attributable to the shareholders of the Company of approximately RMB27.5272 million during the Reporting Period (corresponding period in 2019: approximately RMB182.5680 million), representing a decrease of approximately 85% as compared to the corresponding period in 2019; the unaudited net profit attributable to the shareholders of the Company after deducting the non-recurring profit and loss is expected to be approximately RMB7.8299 million (corresponding period in 2019: unaudited net profit attributable to the shareholders of the Company after deducting the non-recurring profit and loss was approximately RMB183.8932 million), representing a decrease of approximately 96% as compared to the corresponding period in 2019.

As far as the Board is aware, the decrease in profits recorded during the Reporting Period as compared to the corresponding period last year was mainly due to the impact of the continuous spread of the novel coronavirus (“**COVID-19**”) epidemic worldwide during the Reporting Period. During the Reporting Period, stringent measures to prevent and control the COVID-19 epidemic were implemented throughout the People's Republic of China (the “**PRC**”), resulting in a sharp decrease in the number of outpatient consultations and surgeries performed in medical institutions, which led to a year-on-year decrease in the sales revenue of the Group's products during the Reporting Period. Meanwhile, the continuous spread of the COVID-19 epidemic in countries and regions outside the PRC has also caused a significant impact on the production and operation activities of the Company's overseas subsidiaries in the second quarter of 2020. In June 2020, the Company received the Shanghai Songjiang financial policy subsidy of RMB5 million for listing on the Sci-Tech Innovation Market, which had a certain positive impact on the Company's financial statements during the Reporting Period.

The Board also wishes to supplement that starting from the second quarter of 2020, the sales of the Group's products has rebounded significantly, and the revenue of the Group increased by approximately 123% compared to the first quarter of 2020 and returning to approximately 72% of that of the corresponding period last year. In general, the Group remained profitable during the Reporting Period; and the impact of the COVID-19 epidemic on the Group's business is temporary and business demand remains strong in the long run; and in addition, the Group's financial and cash flow conditions remain stable.

The Board hereby reminds the Shareholders and potential investors that the information set out in this announcement is based on a preliminary assessment with reference to the financial information currently available to the Company and has not been reviewed by the audit committee of the Company. The Group is still finalizing the unaudited consolidated interim results for the Reporting Period (the "**Interim Results**"), which are subject to adjustments (if necessary). The Interim Results may differ from the data set out in this announcement. Shareholders and potential investors are advised to read carefully the detailed financial information to be disclosed in the Group's Interim Results, which is expected to be published in late August 2020.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Chairman
Hou Yongtai

Shanghai, the PRC, August 14, 2020

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie and Mr. Huang Ming; and the independent non-executive directors of the Company are Ms. Li Yingqi, Mr. Jiang Zhihong, Mr. Su Zhi, Mr. Yang Yushe and Mr. Zhao Lei.

* For identification purpose only